Action of atorvastatin in combined hyperlipidemia preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 1, 2000, Pages 189-197

  Guerin, Maryse ^a   Lassel, Taous S ^a   Le Goff, Wilfried ^a   Farnier, Michel ^b   Chapman, M John ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Point Medical   (France)

Author keywords

Cholesteryl ester transfer protein activity; HMGCoA reductase inhibitors; Lipoprotein subspecies

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL ARTICLE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL;

EID: 0033958096     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.1.189     Document Type: Article

References (42)

1. Thompson GR, ed. A Handbook of Hyperlipidemia. London, England: Current Science; 1990;69-85, 177-194.
2. Arad Y, Ramakrishnan R, Ginsberg HN. Lovastatin therapy reduces low density lipoprotein apo B level in subjects with combined hyperlipidemia by reducing the production of apo B containing lipoproteins: implications for the pathophysiology of apo B production. J Lipid Res. 1990;31: 567-582.
3. Havel RJ. Trislyceride-rich lipoproteins and atherosclerosis: new perspectives. Am J Clin Nutr. 1994;59:795-799.
4. Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, Shepherd J Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis. 1994;106: 241-253.
5. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Modifications of low-density lipoprotein that increase its atherogenecity. N Engl J Med. 1989;320:915-924.
6. Packard CJ, Shepherd J. Regulation of VLDL production in man: implications for coronary heart disease (CHD). In: Jacotot B, Mathe D, Fruchart J-C, eds. Atherosclerosis XI. Singapore, Elsevier Science; 1998: 789-793.
7. Packard CJ Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol. 1997;17:3542-3556.
8. Guérin M, Bruckert E, Dolphin PJ, Chapman MJ. Absence of cholesteryl ester transfer protein-mediated cholesteryl ester mass transfer from high-density lipoprotein to low-density lipoprotein particles is a major feature of combined hyperlipidemia. Eur J Clin Invest. 1996;26:485-494.
9. Lagrost L. Regulation of cholesteryl ester transfer protein (CETP) activity: review of in vitro and in vivo studies. Biochim Biophys Acta. 1994;1215:209-236.
10. Guérin M, Dolphin PJ, Chapman MJ. A new in vitro method for the simultaneous evaluation of cholesteryl ester exchange and mass transfer between HDL and apo B-containing lipoprotein subspecies: identification of preferential cholesteryl ester acceptors in human plasma. Arterioscler Thromb. 1994;14:199-206.
11. Nigon F, Lesnik P, Rouis M, Chapman MJ. Discrete subspecies of human low-density lipoproteins are heterogeneous in their interaction with cellular LDL receptor. J Lipid Res. 1991;32:1741-1754.
12. Lund-Katz S, Laplaud PM, Phillips MC, Chapman MJ. Apolipoprotein B-100 conformation and particle surface charge in human LDL subspecies: implication for LDL receptor interaction. Biochemistry. 1998;37: 12867-12874.
13. Guérin M, Bruckert E, Dolphin PJ, Turpin G, Chapman MJ. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 1996;16:763-772.
14. Guérin M, Dolphin PJ, Talussot C, Gardette J, Berthezene F, Chapman MJ. Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1995;15: 1359-1368.
15. Dart A, Jerums G, Nicholson G, d'Emden M, Hamilton-Craig I, Tallis G, Best J, West M, Sullivan D, Bracs P, Black D. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol. 1997; 80:39-49.
16. Jones P, Kafonek S, Laurorc I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81:582-587.
17. O'Connor P, Feely J, Shepherd J. Lipid lowering drugs. Br Med J. 1990;300:667-672.
18. Bruckert E, Dejager S, Chapman MJ. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia. Atherosclerosis. 1993;100:91-102.
19. Eisenberg S. Role of fibric acids in the management of hyperlipidemia. Curr Opin Lipidol. 1990;1:34-38.
20. Ooi TC, Heinonen T, Alaupovic P, Davignon J, Leiter L, Lupien PJ, Sniderman AD, Tan MH, Tremblay G, Sorisky A, Shurzinske L, Black DM. Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate. Arterioscler Thromb Vasc Biol. 1997; 17:1793-1799.
21. Kissebah AH, Adams PW, Harrigan P, Wynn V. The mechanism of action of clofibrate and tetranicotinoylfructose (bradilan) on the kinetics of plasma free fatty acid and triglyceride transport in type IV and type V hypertriglyceridaemia. Eur J Clin Invest. 1974;4:163-174.
22. Heller F, Harvengt C. Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects. Eur J Clin Pharmacol. 1983;25:57-63.
23. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwanz SL, Lupien PJ, Jones PH, Haber HE, Black DM. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 1995;15:678-682.
24. Alaupovic P, Heinonen T, Shurzinske L, Black DM. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels. Atherosclerosis. 1997;133:123-133.
25. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 1996;275: 128-133.
26. Bruckert E, Emmerich J, Thomas D, Charpak Y, Bichon L, Clergeot A. Effects of an educational program on cardiovascular risk factors in a French town (Epemon Study): methodology and preliminary results: prevalence of the risk factors. Rev Epidemiol Santé Publique. 1994;42: 128-137.
27. Durrington PN, Mackness MI, Bhatnagar D, Julier K, Frais H, Arrol S, Morgan J, Wood GNI. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinemia. Atherosclerosis. 1998;138:217-225.
28. Chapman MJ, Goldstein S, Lagrange D, Laplaud PM. A density gradient ultracentrifugation procedure for the isolation of the major lipoprotein classes from human plasma. J Lipid Res. 1981;22:339-358.
29. Blanche PJ, Gong EL, Forte TM, Nichols AV. Characterisation of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta. 1981;665:408-419.
30. Ahnadi CE, Berthezene F, Ponsin G. Simvastatin-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins in normolipidemic subjects. Atherosclerosis. 1993;99:219-228.
31. McPherson R, Mann CJ, Tall AR, Hogue M, Martin L, Milne RW, Marcel YL. Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia: relation to cholesteryl ester protein activity and other lipoprotein variables. Arterioscler Thromb. 1991;11:797-804.
32. Bertolini S, Bittolo Bon G, Campbell LM, Farnier M, Langan J, Mahla G, Pauciullo P, Sirtori C, Ergos F, Fayyad R, Nawrocki JW. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis. 1997;130:191-197.
33. Bakker-Arkema RG, Best J, Fayyad R, Heinonen TM, Marais AD, Nawrocki JW, Black DM. A brief review paper of the efficacy and safety of atorvastatin in early clinical trials. Atherosclerosis. 1997;131:17-23.
34. McKenney JM, McCormick LS, Weiss S, Koren M, Kafonek S, Black DM. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Am J Med. 1998;104:137-143.
35. Chapman MJ, Laplaud PM, Luc G, Forgez P, Bruckert E, Goulinet S, Lagrange D. Further resolution of the low density lipoprotein spectrum in normal human plasma: physicochemical characteristics of discrete subspecies separated by density gradient ultracentrifugation. J Lipid Res. 1988;29:442-458.
36. Hunninghake DB. HMG CoA reductase inhibitors. Curr Opin Lipidol. 1992;3:22-28.
37. Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PHR, Newton RS, Huff MW. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs. Arterioscler Thromb Vasc Biol. 1997;17:2589-2600.
38. Mohammadi A, Macri J, Newton R, Romain T, Dulay D, Adeli K. Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2. Arterioscler Thromb Vasc Biol. 1998;18:783-793.
39. Alegret M, Verd JC, Diaz C, Hernandez G, Adzet Y, Sanchez RM, Laguna JC. Effect of hypolipidemic drugs on key enzyme activities related to lipid metabolism in normolipidemic rabbits. Eur J Pharmacol. 1998;347:283-291.
40. Newnham HH, Barter PJ. Changes in particle size of high density lipoproteins during incubation with very low density lipoproteins, cholesteryl ester transfer protein and lipoprotein lipase. Biochim Biophys Acta. 1992;1125:297-304.
41. Jiang XC, Agellon LB, Walsh A, Breslow JL, Tall A. Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. J Clin Invest. 1992;90:1290-1295.
42. Oliveira HCF, Chouinard RA, Agellon LB, Bruce C, Ma L, Walsh A, Breslow JL, Tall AR. Human cholesteryl ester transfer protein gene proximal promoter contains dietary cholesterol positive responsive elements and mediates expression in small intestine and periphery while predominant liver and spleen expression is controlled by 5′ distal sequences. J Biol Chem. 1996;271:31831-31838.